166 related articles for article (PubMed ID: 31925664)
1. Importance of measuring pharmacologically active metabolites of edoxaban: development and validation of an ultra-high-performance liquid chromatography coupled with a tandem mass spectrometry method.
Siriez R; Alpan L; Elasaad K; Devel P; Laloy J; Dogné JM; Douxfils J
J Thromb Thrombolysis; 2020 Apr; 49(3):395-403. PubMed ID: 31925664
[TBL] [Abstract][Full Text] [Related]
2. The edoxaban-M4 metabolite and measurement of edoxaban by chromogenic assays in human plasma.
Siriez R; Yildiz H; Bouvy C; Haguet H; Maloteau V; Hardy M; Mullier F; Dogné JM; Hainaut P; Douxfils J
Res Pract Thromb Haemost; 2022 Mar; 6(3):e12680. PubMed ID: 35434470
[TBL] [Abstract][Full Text] [Related]
3. Effects of the oral, direct factor Xa inhibitor edoxaban on routine coagulation assays, lupus anticoagulant and anti-Xa assays.
Hillarp A; Strandberg K; Baghaei F; Fagerberg Blixter I; Gustafsson KM; Lindahl TL
Scand J Clin Lab Invest; 2018; 78(7-8):575-583. PubMed ID: 30278787
[TBL] [Abstract][Full Text] [Related]
4. Determination of edoxaban equivalent concentrations in human plasma by an automated anti-factor Xa chromogenic assay.
He L; Kochan J; Lin M; Vandell A; Brown K; Depasse F
Thromb Res; 2017 Jul; 155():121-127. PubMed ID: 28535438
[TBL] [Abstract][Full Text] [Related]
5. Determination of rivaroxaban, apixaban and edoxaban in rat plasma by UPLC-MS/MS method.
Zhang WL; Lou D; Zhang DT; Zhang Y; Huang HJ
J Thromb Thrombolysis; 2016 Aug; 42(2):205-11. PubMed ID: 27116356
[TBL] [Abstract][Full Text] [Related]
6. Microdosed Cocktail of Three Oral Factor Xa Inhibitors to Evaluate Drug-Drug Interactions with Potential Perpetrator Drugs.
Mikus G; Foerster KI; Schaumaeker M; Lehmann ML; Burhenne J; Haefeli WE
Clin Pharmacokinet; 2019 Sep; 58(9):1155-1163. PubMed ID: 30828771
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans.
Bathala MS; Masumoto H; Oguma T; He L; Lowrie C; Mendell J
Drug Metab Dispos; 2012 Dec; 40(12):2250-5. PubMed ID: 22936313
[TBL] [Abstract][Full Text] [Related]
8. Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine.
Parasrampuria DA; Mendell J; Shi M; Matsushima N; Zahir H; Truitt K
Br J Clin Pharmacol; 2016 Dec; 82(6):1591-1600. PubMed ID: 27530188
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics of edoxaban and its main metabolite in a dedicated renal impairment study.
Jönsson S; Simonsson US; Miller R; Karlsson MO
J Clin Pharmacol; 2015 Nov; 55(11):1268-79. PubMed ID: 25966665
[TBL] [Abstract][Full Text] [Related]
10. Quantification of Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in Human Serum by UHPLC-MS/MS-Method Development, Validation, and Application.
Lindahl S; Dyrkorn R; Spigset O; Hegstad S
Ther Drug Monit; 2018 Jun; 40(3):369-376. PubMed ID: 29578938
[TBL] [Abstract][Full Text] [Related]
11. The effect of rifampin on the pharmacokinetics of edoxaban in healthy adults.
Mendell J; Chen S; He L; Desai M; Parasramupria DA
Clin Drug Investig; 2015 Jul; 35(7):447-53. PubMed ID: 26068927
[TBL] [Abstract][Full Text] [Related]
12. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
Ruff CT; Giugliano RP; Braunwald E; Morrow DA; Murphy SA; Kuder JF; Deenadayalu N; Jarolim P; Betcher J; Shi M; Brown K; Patel I; Mercuri M; Antman EM
Lancet; 2015 Jun; 385(9984):2288-95. PubMed ID: 25769361
[TBL] [Abstract][Full Text] [Related]
13. Simple LC-MS/MS method using core-shell ODS microparticles for the simultaneous quantitation of edoxaban and its major metabolites in human plasma.
Ariizumi S; Naito T; Hoshikawa K; Akutsu S; Saotome M; Maekawa Y; Kawakami J
J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Jun; 1146():122121. PubMed ID: 32361632
[TBL] [Abstract][Full Text] [Related]
14. Edoxaban: a focused review of its clinical pharmacology.
Lip GY; Agnelli G
Eur Heart J; 2014 Jul; 35(28):1844-55. PubMed ID: 24810388
[TBL] [Abstract][Full Text] [Related]
15. Edoxaban administration following enoxaparin: a pharmacodynamic, pharmacokinetic, and tolerability assessment in human subjects.
Zahir H; Matsushima N; Halim AB; He L; Zhang G; Lee F; Worland V; Mendell J
Thromb Haemost; 2012 Jul; 108(1):166-75. PubMed ID: 22628060
[TBL] [Abstract][Full Text] [Related]
16. A single and multiple postprandial dose study investigating the pharmacokinetics and pharmacodynamics of edoxaban in healthy Chinese volunteers
.
Chen X; Liu D; Wu Y; Liu Y; Song H; Jiang J; Hu P
Int J Clin Pharmacol Ther; 2017 Mar; 55(3):256-263. PubMed ID: 28025966
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis.
Parasrampuria DA; Marbury T; Matsushima N; Chen S; Wickremasingha PK; He L; Dishy V; Brown KS
Thromb Haemost; 2015 Apr; 113(4):719-27. PubMed ID: 25566930
[TBL] [Abstract][Full Text] [Related]
18. A UHPLC-MS/MS method to simultaneously quantify apixaban, edoxaban and rivaroxaban in human plasma and breast milk: For emerging lactation studies.
Zhao Y; Couchman L; Kipper K; Arya R; Patel JP
J Chromatogr B Analyt Technol Biomed Life Sci; 2020 May; 1144():122095. PubMed ID: 32251991
[TBL] [Abstract][Full Text] [Related]
19. Paramagnetic micro-particles as a tool for rapid quantification of apixaban, dabigatran, edoxaban and rivaroxaban in human plasma by UHPLC-MS/MS.
Wiesen MHJ; Blaich C; Streichert T; Michels G; Müller C
Clin Chem Lab Med; 2017 Aug; 55(9):1349-1359. PubMed ID: 28328524
[TBL] [Abstract][Full Text] [Related]
20. Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review.
Cuker A; Husseinzadeh H
J Thromb Thrombolysis; 2015 Apr; 39(3):288-94. PubMed ID: 25669624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
